Skip to main content

Efficacy: Consistent and durable

With Doptelet, give your patients the sustained platelet response they need1

Median platelet count was consistently higher with Doptelet vs placebo from Day 8 (80.5 x 109/L vs 8 x 109/L)*1

Median platelet count over the 6-month treatment period of the core Phase 3 study phase1

Doptelet median platelet count
94 percent circle diagram

of patients, who received Doptelet during the core and/or extension phase achieved response2

Red icon 9.2 months

was the median duration that patients stayed on Doptelet treatment during a 17-month, retrospective, multicentre analysis3

Uncover the TPO-RA experience
Doptelet was effective in both TPO-RA-naïve patients and those who had switched from another TPO-RA2

In a post hoc subgroup analysis of the Phase 3 study, treatment with Doptelet was equally effective among patients with and without prior TPO-RA experience2

12.4 weeks
The TPO-RA-naïve group achieved response with Doptelet for a median of 12.4 weeks at or above 50 x 109/L2
66%
(21/32) of Doptelet patients were TPO-RA-naïve2

 

12.7 weeks
The TPO-RA experienced group achieved response with Doptelet for a median of 12.7 weeks at or above 50 x 109/L2
34%
(11/32) of Doptelet patients have previously received treatment with a different TPO-RA2

Dive into patient experiences with Doptelet in the real-world

Read more

Explore which food type and supplements do not affect Doptelet absorption

Find out

*Phase 3 study.1
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

References

1. Jurczak W, et al. Br J Haematol. 2018;183(3):479–490;
2. Jain S, et al. Platelets. 2023;34(1):2195016;
3. Al-Samkari H, et al. Br J Haematol. 2022;197(3):359–366.